We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Blood Gas and Electrolyte Analyzer Provides Results in 50 Seconds

By LabMedica International staff writers
Posted on 09 Sep 2008
A new blood gas and electrolyte (BGE) analyzer provides high quality measurements in just 50 seconds including blood gases (pH, PCO2, PO2), electrolytes (Na+, K+, Ca++, Cl-), and hematocrit (Hct). More...
From the measurements a number of parameters are additionally calculated, for instance, base excess (BE).

Roche Diagnostics (Basel, Switzerland) announced the launch of the cobas b 121 blood gas analyzer in the EMEA region (Europe, Middle East, Africa), Asian, and Latin American markets. The cobas b 121 system meets expectations for a low cost, effective instrument for the rapid determination of blood gases and electrolytes.

The system supports clinical laboratories in facing the challenge of increasing cost pressure on healthcare. High levels of automation and low levels of maintenance mean very little operator intervention. This combined with its economy mode, maintenance-free, long-life sensors, and reusable waste bottles help to save costs.

The already existing cobas b 121 platform was simplified and reduced to the analytes needed for the rapid determination of blood gas and electrolytes status as well as acid base disorders. Although the complexity has been reduced on the system, it has kept the touch screen interface and high levels of on-board data management and connectivity. Customers currently using separate analyzers for blood gas and electrolyte measurements can now consolidate blood gases and electrolytes on one analyzer for greater efficiency.

The instrument is one of the fastest BGE systems for medium to high throughput (30 samples per hour) situations, and the maintenance-free sensors and high volume, reusable reagent bottles make it easy to operate and reliable. Calibrations are run automatically with a liquid calibration system, making it entirely gas-free.

Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.

Related Links:
Roche Diagnostics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.